Sienna Diagnostics Ltd is a Melbourne based biotechnology company, that has developed, and commercialized, a new technology with application in the early detection of cancer. Sienna has proprietary technology it has fully commercialized the first of its numerous applications, with CE-marked (EU), Medicare rebate approved here in Australia, and in the USA they have also have Medicare approval with a $108 rebate per test.  Sequoia (part of the Interprac Group) are handling the Initial Public Offering (IPO) of Sienna at a a competitive valuation and raising up to $6 million at 20 cents per share.

Sienna has built a strong team and a global scientific, clinical, and commercial network. We believe the company has solid management and well credentialed and experienced board.  It has as solid technology and has the potential for a compelling niche in the US market, let alone globally.  The offer is open  until fully subscribed or at the latest 17th July 2017. Further information can be obtained at http://www.siennadiagnostics.com.au/IPO.

For eligibility and suitability within your portfolio, please contact our office MDK Wealth Management (03) 5133 9117